GeneDx Holdings Corp. (WGS)

GeneDx Holdings Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-21.02	-52.29	-175.77	-548.98	-245.39
Depreciation & Amortization	25.22	21.95	33.73	59.31	21.81
Stock-Based Compensation	32.16	9.14	-0.33	41.98	41.98
Other Adjustments	12.51	17.44	0.45	94.66	-194.35
Change in Receivables	-36.23	-5.18	10.53	5.53	5.54
Changes in Inventories	-3.44	-2.59	0.98	2.35	-10.62
Changes in Accounts Payable	12.1	-20.52	-49.17	34.46	25.92
Changes in Unearned Revenue	-	-	-	-	-1.31
Changes in Other Operating Activities	11.97	3.54	-0.58	-8.46	-11.44
Operating Cash Flow	33.28	-28.5	-180.15	-319.16	-190.43
Capital Expenditures	-19.02	-5.49	-5.25	-7.16	-9.4
Sale of Property, Plant & Equipment	-	-	4.03	-	-
Purchases of Intangible Assets	-	-	-0.46	-7.17	-11.39
Purchases of Investments	-	-66.3	-47.67	-	-
Proceeds from Sale of Investments	46.03	41.66	17.77	-	-
Payments for Business Acquisitions	-32.86	-	-67.82	-127	-
Investing Cash Flow	-61.52	-30.13	-43.73	-141.33	-20.79
Long-Term Debt Issued	-	-	48.55	-	-
Long-Term Debt Repaid	-1.21	-0.5	-2	-	-9.74
Net Long-Term Debt Issued (Repaid)	-1.21	-0.5	46.55	-	-9.74
Issuance of Common Stock	51.69	47.39	143.29	200.61	793.96
Repurchase of Common Stock	-	-	-	-	-230.67
Net Common Stock Issued (Repurchased)	51.69	47.39	143.29	200.61	563.29
Other Financing Activities	-2.45	-2.73	-3.6	-3.29	-59.82
Financing Cash Flow	48.03	44.16	186.24	197.32	493.73
Net Cash Flow	19.79	-14.47	-37.64	-263.17	282.51
Free Cash Flow	14.26	-33.99	-185.4	-326.31	-199.83
FCF Margin	3.34%	-11.13%	-91.52%	-139.04%	-94.17%
Free Cash Flow Per Share	0.50	-1.26	-7.63	-	-61.02
Levered Free Cash Flow	4.61	-55.89	-149.5	-468.47	-240.18
Unlevered Free Cash Flow	13.84	-26.16	-199.93	-532.38	-431.2

Updated Feb 23, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q